2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Antibody Therapy, Transfusion, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

1197 Identification of g-protein-coupled receptor signaling as an augmenter of human neutrophil function against invasive candida.

Elizabeth Trull, BS, David Brian Sykes, MD, PhD2, Vince Ho, MD, MBA3, Michael Mansour, MD, PhD4
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 Massachusetts General Hospital, Boston, Massachusetts, United States
3 Uniformed Services University, Chevy Chase, Maryland, United States
4 Massachusetts General Hospital, Boston, Massachusetts, United States

Neutrophils are a critical part of the innate immune system, defending the host against invasive fungal pathogens by mediating early recognition and elimination through coordinated signaling and effector responses. However, this defense is compromised in patients receiving cytotoxic chemotherapy or ionizing radiation, where bone marrow suppression leads to profound reductions in both neutrophil number and function. The result is a window of vulnerability to life-threatening opportunistic infections that, despite a plethora of effective antimicrobials, continue to result in high morbidity and mortality.

Current antifungal therapies focus on targeting pathogens, but do not address the underlying immune deficit that renders these patients vulnerable in the first place. Alternatively, host-directed therapeutics have the potential to enhance pathogen clearance without driving resistance by harnessing the host’s own defenses, yet remain limited and largely unexplored. We sought to address this potentially transformative therapeutic approach by exploring small molecules that could augment the neutrophil response to fungal pathogens.

To identify such compounds, we conducted a high-throughput screen of 2,816 structurally diverse, FDA-approved small molecules using freshly isolated primary human neutrophils stimulated with Candida albicans and the chemoattractant fMLP. Eight compounds were identified that significantly and reproducibly modulated reactive oxygen species (ROS) production by neutrophils following fungal challenge. Strikingly, despite their structural diversity, the mechanisms of action of all 8 hits converged on G protein-coupled receptor (GPCR) signaling.

To validate the effects on ROS production observed in the primary screen, hits were tested in several functional assays to quantify various neutrophil functions. We found that GPCR modulation not only alters ROS production, but also additional neutrophil functions such as phagocytosis, degranulation, ectodomain shedding, and swarming. These results demonstrate that the effects of GPCR signaling modulation extend beyond a single effector function to encompass a comprehensive neutrophil response and support the potential of small-molecule modulation as a therapeutic target.

Taken together, these data further suggest that GPCR signaling may be used as a regulator of the neutrophil response to fungal pathogens. This information supports its potential as a therapeutic target and prompted us to investigate whether GPCR signaling intersects with the canonical neutrophil pathway, Dectin-1. Defining this crosstalk would identify a therapeutically actionable target through which the host immune response could be selectively amplified.

This work provides a compelling rationale for pairing conventional antifungal therapy with a small-molecule host immune enhancer, an approach that not only targets the pathogen but also enhances host defense by harnessing neutrophils. The potential of these FDA-approved GPCR modulators for clinical translation is tangible. If validated, harnessing this pathway could fundamentally reframe the treatment of invasive fungal infections, offering genuine promise as a new standard of care for the patients most at risk, such as stem-cell transplant recipients.
Michael Mansour, MD, PhD: Vertex - Consultancy (Includes expert testimony)